Cytokine gene expression in healing and non-healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi-quantitative RT-PCR

Scandinavian Journal of Immunology

Volumn 54, Issue 4, 2001, Pages 414-420

  Habibi, G R ^a   Khamesipour, A ^b   McMaster, W R ^c   Mahboudi, F ^d  

^a RAZI VACCINE AND SERUM RESEARCH INSTITUTE   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN; GLYCOPROTEIN 63; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEALING; IMMUNE RESPONSE; IN VITRO STUDY; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN LEISHMANIASIS;

ADOLESCENT; ADULT; AGED; ANIMALS; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; LEISHMANIASIS, CUTANEOUS; LEUKOCYTES, MONONUCLEAR; MALE; METALLOENDOPEPTIDASES; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; WOUND HEALING;

EID: 0034786590     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2001.00990.x     Document Type: Article

References (43)

1. The immunobiology of leishmaniasis
2. Cutaneous leishmaniasis
3. A brief review of the epidemiology of various types of leishmaniasis in Iran
4. Experiences with vaccines against cutaneous leishmaniasis: Of men and mice
5. Comparative safety and immunogenecity trial of two killed Leishmania major vaccines with or without BCG in human volunteers
6. Randomized vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam
7. Vaccination against cutaneous leishmaniasis in a murine model I. Induction of protective immunity with a soluble extract of promastigotes
8. Transferring growth factor-alpha in Leishmania infection: A parasite escape mechanism
9. Interleukin-12: Initiation cytokine for cell-mediated immunity
10. Natural killer cell stimulatory factor (IL-12) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells
11. LeIF: A recombinant Leishmania protein that induces an IL-12 mediated Th1 cytokine profile
12. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection
13. Leishmania pifanoi amasigote antigens protect mice against cutaneous leishmaniasis
14. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multi copy gene family
15. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a Th1 type of immune response
16. A recombinant Leishmania antigen that stimulate human peripheral blood mononuclear cells to express a Th1 type cytokine profile and to produce interleukin-12
17. T cell responses and immunity to experimental infection with Leishmania major
18. Kinetics of cell mediated immunity developing during the course of Leishmania major infection in healer and non-healer mice
19. Reciprocal expression of interferon gamma or IL-4 during the resolution or progression of murine leishmaniasis
20. Two types of murine helper T cell clone 1: Definition according to profiles of lymphokine activities and secreted proteins
21. IL-10 acts on the antigen presenting cell to inhibit cytokine production by Th1 cells
22. Interleukin-12/T cell stimulating factor, a cytokine with multiple effects on T helper 1 (Th1) but not on Th2 cells
23. T cell and cytokine responses in leishmaniasis
24. Analysis of viability in lymphocyte transformation tests
25. A new portable device for automatic controlled-gradient cryopreservation of blood mononuclear cells
26. High level expression of Leishmania major gp63 gene in different strains of E. coli under the control of lambda p1 promoter
27. Human T cell responses to gp63 a surface antigen of Leishmania
28. In vivo cytokine profiles in patients with kala-azar
29. Splenic cytokine responses in indian kala-azar before and after treatment
30. Transcription of the dystrophin gene in human muscle and non-muscle tissues
31. Direct quantitation of picomolar concentrations of mRNAs by mathematical analysis of a reverse transcription/exponential polymerase chain reaction assay
32. Leishmania-specific T cells expressing interferon-gamma (IFN-γ) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis
33. Production of interferon-gamma and interleukin-4 by human T cells recognizing Leishmania Lipophosphoglycan-associated protein
34. Comparison of the immune profile of Anon-healing cutaneous leishmaniasis patients with those with active lesions and those who have recovered from infection
35. Long-term protection of mice against Leishmania major with a synthetic peptide vaccine
36. Vaccination against Leishmania major in a CBA mouse model of infection: Role of adjuvants and mechanism of protection
37. ISCOMs vaccine against experimental leishmaniasis
38. Biochemical analysis immunogenicity of Leishmania major amastigote reactions in cutaneous leishmaniasis
39. Invasion, control and persistence of Leishmania parasites
40. Interleukin-10 production correlates with pathology in human Leishmania donovani infection
41. Indication of the protective role of natural killer cells in human cutaneous leishmaniasis of endemicity
42. IL-12 is required for natural killer cell activation and subsequent T helper cell development in experimental leishmaniasis
43. IFN-γ modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis